The latest report from a group financed and backed by the pharmaceutical industry “continues to misrepresent” the 340B Drug Pricing Program and its “successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive health services,” AHA Executive Vice President Tom Nickels writes today in an AHA Stat blog post. Nickels says the report “attempts to mislead the debate by comparing changes in the ‘charity care’ provided by a small sample size of 160 disproportionate share hospitals (out of 2,448 hospitals) that participate in the 340B program,” and he highlights the many benefits 340B hospitals provide to the patients and communities they serve. "We hope policymakers won’t be diverted by this self-serving report from the important job of finding solutions to bring down the exorbitant cost of many prescription drugs that is threatening the availability of life-saving medications for millions of Americans,” Nickels writes.

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A KFF analysis published Aug. 20 provides a state-by-state allocation of Congressional Budget Office estimates that 10 million people could be uninsured by…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Headline
The Centers for Medicare & Medicaid Services Innovation Center Aug. 12 released an FAQ on the Wasteful and Inappropriate Service Reduction Model, a six-…
Headline
The AHA on Aug. 14 at 1 p.m. ET will host a webinar on age-friendly health systems and how they can strengthen care delivery. Adam Koontz, senior director of…
Headline
The U.S. Departments of Labor, Health and Human Services, and the Treasury announced Aug. 7 that they are reconsidering the definition of short-term, limited-…